Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer, July 2022

Free Subscription


Abstracts

Retrieve all available abstracts of the following 224 articles:
HTML format


 

Single Articles

  1. VAN WILPE S, Sultan S, Gorris MAJ, Somford DM, et al
    Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
    Cancer Immunol Immunother. 2022 Jun 30. pii: 10.1007/s00262-022-03234.
    PubMed    
    Abstract available

  2. YAO J, Liu Y, Yang J, Li M, et al
    Single-Cell Sequencing Reveals that DBI is the Key Gene and Potential Therapeutic Target in Quiescent Bladder Cancer Stem Cells.
    Front Genet. 2022;13:904536.
    PubMed    
    Abstract available

  3. YE F, Liang Y, Cheng Z, Liu Y, et al
    Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer.
    Front Immunol. 2022;13:911902.
    PubMed    
    Abstract available


  4. Novel lncRNA LINC01614 Facilitates Bladder Cancer Proliferation, Migration and Invasion Through the miR-217/RUNX2/Wnt/beta-Catenin Axis [Retraction].
    Cancer Manag Res. 2022;14:2105-2106.
    PubMed    
    Abstract available

  5. XIAO Y, He L, Dong Y, Huang Y, et al
    Highly Expressed LINC00958 Modulates the Growth and Epithelial-Mesenchymal Transition of Bladder Cancer Cells Through SAPK/JNK Signaling Pathway.
    Cancer Biother Radiopharm. 2022 Jun 29. doi: 10.1089/cbr.2022.0005.
    PubMed    
    Abstract available


  6. Erratum notice for: "Suppressive effect of platycodin D on bladder cancer through microRNA-129-5p-mediated PABPC1/PI3K/AKT axis inactivation" [Braz J Med Biol Res 2021;54(3):e10222].
    Braz J Med Biol Res. 2022;55:e10222erratum.
    PubMed    
    Abstract available

  7. SAEEDIAN A, Safaei AM, Azimi A, Kolahdouzan K, et al
    Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy.
    J Cancer Res Clin Oncol. 2022 Jun 28. pii: 10.1007/s00432-022-04153.
    PubMed    
    Abstract available

  8. MARTIN-WAY D, Puche-Sanz I, Cozar JM, Zafra-Gomez A, et al
    Genetic variants of antioxidant enzymes and environmental exposures as molecular biomarkers associated with the risk and aggressiveness of bladder cancer.
    Sci Total Environ. 2022 Jun 25:156965. doi: 10.1016/j.scitotenv.2022.156965.
    PubMed    
    Abstract available

  9. KHALIL H, Hammam OA, Kamel A
    Detection of Epithelial-Mesenchymal Transition Markers in High Grade Bladder Cancer and Special Variants of Urothelial Carcinoma.
    Asian Pac J Cancer Prev. 2022;23:2079-2087.
    PubMed    
    Abstract available

  10. BICCHETTI M, Simone G, Giannarini G, Girometti R, et al
    A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study.
    Radiol Med. 2022 Jun 28. pii: 10.1007/s11547-022-01513.
    PubMed    
    Abstract available

  11. WANG HJ, Cai Q, Huang YP, Li MQ, et al
    Amide Proton Transfer-weighted MRI in Predicting Histologic Grade of Bladder Cancer.
    Radiology. 2022 Jun 28:211804. doi: 10.1148/radiol.211804.
    PubMed    
    Abstract available

  12. LI Y, Jiang L, Wang Z, Wang Y, et al
    Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry.
    Anal Chem. 2022 Jun 28. doi: 10.1021/acs.analchem.2c01890.
    PubMed    
    Abstract available

  13. NODA Y, Naiki T, Sugiyama Y, Nagai T, et al
    Survival outcome after reduced-port laparoscopic radical cystectomy for bladder cancer: long-term follow-up analysis.
    Oncology. 2022 Jun 27. pii: 000525554. doi: 10.1159/000525554.
    PubMed    
    Abstract available

  14. LEEMING RC, Koutros S, Karagas MR, Baris D, et al
    Diet quality, common genetic polymorphisms, and bladder cancer risk in a New England population-based study.
    Eur J Nutr. 2022 Jun 27. pii: 10.1007/s00394-022-02932.
    PubMed    
    Abstract available

  15. JAKIMOW K, Sznajder K
    VESICAL IMAGING-REPORTING AND DATA SYSTEM - A NEW APPROACH TO BLADDER CANCER STAGING.
    Wiad Lek. 2022;75.
    PubMed    
    Abstract available

  16. SUN X, Xin S, Jin L, Zhang Y, et al
    Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
    Bioengineered. 2022;13:13986-13999.
    PubMed    
    Abstract available

  17. DE NUNZIO C, Lombardo R, Cicione A
    Early or Delayed Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Hard Dilemma to Solve.
    Eur Urol Open Sci. 2022;42:17-18.
    PubMed    


  18. BAI Y, Wang H, Wu X, Weng M, et al
    Study on Molecular Information Intelligent Diagnosis and Treatment of Bladder Cancer on Pathological Tissue Image.
    Front Med (Lausanne). 2022;9:838182.
    PubMed    
    Abstract available

  19. BARBUR E, Doganca T, Obek C
    Safe use of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer during breastfeeding: a case report.
    Immunotherapy. 2022 Jun 27. doi: 10.2217/imt-2021-0203.
    PubMed    
    Abstract available

  20. LIN L, Guo X, Ma Y, Zhu J, et al
    Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis.
    Eur J Surg Oncol. 2022 Jun 13. pii: S0748-7983(22)00489.
    PubMed    
    Abstract available

  21. WU X, Wei Y, Lin R, Chen P, et al
    Multi-responsive mesoporous polydopamine composite nanorods cooperate with nano-enzyme and photosensitizer for intensive immunotherapy of bladder cancer.
    Immunology. 2022 Jun 25. doi: 10.1111/imm.13534.
    PubMed    
    Abstract available

  22. MAHMOUD AM, Frank I, Orme JJ, Lavoie RR, et al
    Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.
    BMC Urol. 2022;22:90.
    PubMed    
    Abstract available

  23. POHAR KS, Patel S, Lotan Y, Trabulsi E, et al
    Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study.
    Urol Oncol. 2022 Jun 21. pii: S1078-1439(22)00144.
    PubMed    
    Abstract available

  24. YAMAGUCHI R, Shimizu Y, Nakayasu R, Utsunomiya N, et al
    [A Case of Bladder Plasmacytoma Diagnosed during Treatment of Multiple Myeloma].
    Hinyokika Kiyo. 2022;68:149-153.
    PubMed    
    Abstract available

  25. TAKAHASHI R, Kinase S, Yanagihashi R, Ishitsuka R, et al
    [A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine].
    Hinyokika Kiyo. 2022;68:145-148.
    PubMed    
    Abstract available

  26. AKKARY R, Guerin F, Chargari C, Jochault L, et al
    Long-term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder-prostate rhabdomyosarcoma: A single-team experience.
    Pediatr Blood Cancer. 2022;69:e29532.
    PubMed    
    Abstract available

  27. KIJIMA T, Kubo T, Nishihara D, Nukui A, et al
    Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients.
    Sci Rep. 2022;12:10617.
    PubMed    
    Abstract available

  28. KIM Y, Choi WJ, Oh J, Kim JK, et al
    Compact Smartphone-Based Laser Speckle Contrast Imaging Endoscope Device for Point-of-Care Blood Flow Monitoring.
    Biosensors (Basel). 2022;12.
    PubMed    
    Abstract available

  29. MENDREK M, Witt JH, Sarychev S, Liakos N, et al
    Reporting and grading of complications for intracorporeal robot-assisted radical cystectomy: an in-depth short-term morbidity assessment using the novel Comprehensive Complication Index((R)).
    World J Urol. 2022;40:1679-1688.
    PubMed    
    Abstract available

  30. LAUKHTINA E, Boehm A, Peyronnet B, Bravi CA, et al
    Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.
    World J Urol. 2022;40:1689-1696.
    PubMed    
    Abstract available

  31. VEJLGAARD M, Maibom SL, Joensen UN, Thind PO, et al
    Quality of life and secondary outcomes for open versus robot-assisted radical cystectomy: a double-blinded, randomised feasibility trial.
    World J Urol. 2022;40:1669-1677.
    PubMed    
    Abstract available

  32. ARORA A, Zugail AS, Pugliesi F, Cathelineau X, et al
    Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy.
    World J Urol. 2022;40:1697-1705.
    PubMed    
    Abstract available

  33. PUZYRENKO A, Nomani L, Iczkowski K, Giorgadze T, et al
    Small cell carcinoma of the urinary bladder: Distinctive cytological characteristics and Cyto-histologic correlation.
    Ann Diagn Pathol. 2022;59:151947.
    PubMed    
    Abstract available

  34. DEL GIUDICE F, Flammia RS, Pecoraro M, Moschini M, et al
    The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations.
    World J Urol. 2022;40:1617-1628.
    PubMed    
    Abstract available

  35. HO KKF, Lal V, Hagley D, Bingley J, et al
    Systematic Review of Case Reports of Bacillus Calmette-Guerin Vascular Infections.
    Ann Vasc Surg. 2022;83:369-377.
    PubMed    
    Abstract available

  36. LOBO S, Gaze MN, Slater O, Hoskin P, et al
    Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma.
    Pediatr Blood Cancer. 2022;69:e29574.
    PubMed    
    Abstract available

  37. FANG T, Tang C, Yin J, Wang H, et al
    Magnetic multi-enzyme cascade combined with liquid chromatography tandem mass spectrometry for fast DNA digestion and quantitative analysis of 5-hydroxymethylcytosine in genome of human bladder cancer T24 cells induced by tetrachlorobenzoquinone.
    J Chromatogr A. 2022;1676:463279.
    PubMed    
    Abstract available

  38. PHE V
    Bladder Cancer in Neurogenic Patients.
    World J Urol. 2022 Jul 8. pii: 10.1007/s00345-022-04089.
    PubMed    


  39. ZHANG Y, Wang Y, Wang J, Zhang K, et al
    The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis.
    Front Genet. 2022;13:852708.
    PubMed    
    Abstract available

  40. RUIZ DE PORRAS V
    Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?
    Cancer Drug Resist. 2022;5:339-343.
    PubMed    
    Abstract available

  41. KE H, Qiu D, Cong Z
    Prognosis Analysis and Perioperative Research of Elderly Patients with Non-Muscle-Invasive Bladder Cancer under Computed Tomography Image of Three-Dimensional Reconstruction Algorithm.
    Contrast Media Mol Imaging. 2022;2022:6168528.
    PubMed    
    Abstract available

  42. HU K, Zhu J, Li P, Ying L, et al
    Multiorientation Simultaneous Computation of Back-Projection CT Image Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.
    Comput Math Methods Med. 2022;2022:6731491.
    PubMed    
    Abstract available

  43. MARTIN A, Woolbright BL, Umar S, Ingersoll MA, et al
    Bladder cancer, inflammageing and microbiomes.
    Nat Rev Urol. 2022 Jul 7. pii: 10.1038/s41585-022-00611.
    PubMed    
    Abstract available

  44. LIU X, He Y, Tong Y, Huang Q, et al
    PODNL1 promotes cell migration and regulates the epithelial/mesenchymal transition process in bladder cancer.
    Biochem Biophys Res Commun. 2022;620:165-172.
    PubMed    
    Abstract available

  45. LEE HW, Seo HK
    Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder.
    Investig Clin Urol. 2022;63:369-372.
    PubMed    


  46. GOTO Y, Tanaka S, Maruo M, Sugawara S, et al
    Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis.
    IJU Case Rep. 2022;5:304-307.
    PubMed    
    Abstract available

  47. SONG Q, Yu H, Cheng Y, Han J, et al
    Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment.
    J Transl Med. 2022;20:308.
    PubMed    
    Abstract available

  48. XU T, Gu W, Wang X, Xia L, et al
    Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature.
    World J Surg Oncol. 2022;20:226.
    PubMed    
    Abstract available

  49. HEMENWAY G, Lewis B, Ghatalia P, Anari F, et al
    Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy.
    Eur Urol Oncol. 2022 Jul 2. pii: S2588-9311(22)00107.
    PubMed    
    Abstract available

  50. KEMP-CASEY A, Mintzes B, Morrow RL, Dormuth CR, et al
    Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: an interrupted time series study.
    Pharmacoepidemiol Drug Saf. 2022 Jul 5. doi: 10.1002/pds.5508.
    PubMed    
    Abstract available

  51. HU QG, Yang Z, Chen JW, Kazobinka G, et al
    MiR-183-5p-PNPT1 Axis Enhances Cisplatin-induced Apoptosis in Bladder Cancer Cells.
    Curr Med Sci. 2022 Jul 5. pii: 10.1007/s11596-022-2580.
    PubMed    
    Abstract available

  52. GUPTA S, Erickson LA
    Postirradiation Angiosarcoma of the Urinary Bladder.
    Mayo Clin Proc. 2022;97:1406-1408.
    PubMed    


  53. TAN W, Yuan Y, Huang H, Ma J, et al
    Comprehensive analysis of autophagy related long non-coding RNAs in prognosis, immunity, and treatment of muscular invasive bladder cancer.
    Sci Rep. 2022;12:11242.
    PubMed    
    Abstract available

  54. ZHENG X, Xu H, Lin T, Tan P, et al
    CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Comput Biol Med. 2022;147:105727.
    PubMed    
    Abstract available

  55. WANG C, Wan H, Zhang H, Yang B, et al
    Characterization of Ligand-Receptor Pair in Bladder Cancer Develops a Validated Scoring Model for Prognosis and Treatment Response.
    Front Cell Dev Biol. 2022;10:915798.
    PubMed    
    Abstract available

  56. KOLL FJ, Schwarz A, Kollermann J, Banek S, et al
    CK5/6 and GATA3 Defined Phenotypes of Muscle-Invasive Bladder Cancer: Impact in Adjuvant Chemotherapy and Molecular Subtyping of Negative Cases.
    Front Med (Lausanne). 2022;9:875142.
    PubMed    
    Abstract available

  57. SHANG X, Na X, Wang L, Yang Z, et al
    Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells.
    Evid Based Complement Alternat Med. 2022;2022:8110796.
    PubMed    
    Abstract available

  58. CHI BJ, Sun Y, Quan LL, Zhao JT, et al
    Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells.
    Dis Markers. 2022;2022:5709259.
    PubMed    
    Abstract available

  59. KUMAR P, Sharma S, Sundriyal D, Navria SC, et al
    An Institution-Based Demographic Study of Urinary Bladder Cancer from North India.
    Indian J Surg Oncol. 2022;13:432-434.
    PubMed    
    Abstract available

  60. GUO Y, Zheng Z, Zhang W, Mao S, et al
    Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer.
    Ther Adv Med Oncol. 2022;14:17588359221108690.
    PubMed    
    Abstract available

  61. MOREO E, Uranga S, Pico A, Gomez AB, et al
    Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  62. WENG M, Bai Y, Xu L, Chang C, et al
    Comparison of PD-L1 detection methods, platforms and reagents in bladder cancer.
    Ann Diagn Pathol. 2022;60:151986.
    PubMed    
    Abstract available

  63. YANG Y, Hu H, Chen L, Zhang H, et al
    A new survival model based on ferroptosis-related genes (FRGS) for prognostic prediction in bladder cancer.
    Actas Urol Esp (Engl Ed). 2022 Jun 29. pii: S2173-5786(22)00046.
    PubMed    
    Abstract available

  64. HUANG W, Zhang C, Xiong S, Zhou X, et al
    miR-1307-5p suppresses proliferation and tumorigenesis of bladder cancer via targeting MDM4 and the Hippo signaling pathway.
    Discov Oncol. 2022;13:57.
    PubMed    
    Abstract available

  65. RICHTERS A, Leliveld AM, Goossens-Laan CA, Aben KKH, et al
    Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry.
    World J Urol. 2022 Jul 1. pii: 10.1007/s00345-022-04080.
    PubMed    
    Abstract available

  66. LIU S, Chen X, Lin T
    Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.
    J Adv Res. 2022;39:187-202.
    PubMed    
    Abstract available

  67. CHEN H, Wang Z, Yang N, Zhang J, et al
    Decorin inhibits proliferation and metastasis in human bladder cancer cells by upregulating P21.
    Medicine (Baltimore). 2022;101:e29760.
    PubMed    
    Abstract available

  68. ZENG W, Swee DS
    Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.
    Medicine (Baltimore). 2022;101:e29731.
    PubMed    
    Abstract available

  69. ZHANG L, Ding D, Liu J, Liu J, et al
    Identification of prognostic and immunotherapy-related eRNA ID2-AS1 in bladder cancer.
    Medicine (Baltimore). 2022;101:e29759.
    PubMed    
    Abstract available

  70. ZHAO X, Li D, Zhao ST, Zhang Y, et al
    MiRNA-616 aggravates the progression of bladder cancer by regulating cell proliferation, migration and apoptosis through downregulating SOX7.
    Eur Rev Med Pharmacol Sci. 2022;26:4158.
    PubMed    
    Abstract available

  71. JI J, Li H, Chen J, Wang W, et al
    Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycleassociated protein 3.
    Int J Mol Med. 2022;50.
    PubMed    
    Abstract available

  72. MEHRNOUSH V, De Lima SG, Kotb A, Hyndman ME, et al
    The association of bladder cancer and Cannabis: A systematic review.
    Arch Ital Urol Androl. 2022;94:248-251.
    PubMed    
    Abstract available

  73. ARIAFAR A, Salehipour M, Zeyghami S, Rezaei M, et al
    The effect of retroperitonealization of ureteroileal anastomosis on perioperative complications of radical cystectomy with ileal conduit urinary diversion.
    Arch Ital Urol Androl. 2022;94:150-154.
    PubMed    
    Abstract available

  74. MALINARIC R, Mantica G, Balzarini F, Terrone C, et al
    Extraperitoneal cystectomy with ureterocutaneostomy derivation in fragile patients - should it be performed more often?
    Arch Ital Urol Androl. 2022;94:144-149.
    PubMed    
    Abstract available

  75. PEREIRA JN, Reis JD, Braga I, Freitas R, et al
    Variant histologies of urothelial carcinoma: Does it change the survival outcomes in patients managed with radical cystectomy?
    Arch Ital Urol Androl. 2022;94:138-143.
    PubMed    
    Abstract available

  76. LEONARDI R, Calarco A, Falcone L, Grasso V, et al
    Endoscopic laser en bloc removal of bladder tumor. Surgical radicality and improvement of the pathological diagnostic accuracy.
    Arch Ital Urol Androl. 2022;94:134-137.
    PubMed    
    Abstract available

  77. PANG K, Dong Y, Hao L, Shi ZD, et al
    ERH Interacts With EIF2alpha and Regulates the EIF2alpha/ATF4/CHOP Pathway in Bladder Cancer Cells.
    Front Oncol. 2022;12:871687.
    PubMed    
    Abstract available

  78. STANGL-KREMSER J, Lambertini L, Di Maida F, Martinez-Fundichely A, et al
    Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines.
    Eur Urol Focus. 2022 Jun 27. pii: S2405-4569(22)00133.
    PubMed    
    Abstract available

  79. LIU Z, Liu X, Liu F, Zhao H, et al
    The comprehensive and systematic identification of BLCA-specific SF-regulated, survival-related AS events.
    Gene. 2022;835:146657.
    PubMed    
    Abstract available

  80. YUAN L, Gero M, Zia S, Aryal SC, et al
    Cyto-histo correlation and false-negative urine: Before and after the Paris system for reporting urinary cytology.
    Diagn Cytopathol. 2022;50:404-410.
    PubMed    
    Abstract available

  81. GIM G, Kim Y, Park Y, Kim MJ, et al
    Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.
    Oncologist. 2022;27:525-531.
    PubMed    
    Abstract available

  82. ZHOU Q, Wu WW, Yu CL, Wang P, et al
    Saikosaponin A Inhibits Growth of Human Bladder Carcinoma T24 and 5637 Cells Both in Vitro and in Vivo.
    Biol Pharm Bull. 2022;45:863-871.
    PubMed    
    Abstract available

  83. YANG X, Wang Y, Jiao W, Li J, et al
    Application of 5G technology to conduct tele-surgical robot-assisted laparoscopic radical cystectomy.
    Int J Med Robot. 2022;18:e2412.
    PubMed    
    Abstract available

  84. MORI K, Schuettfort VM, Egawa S, Comperat E, et al
    ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
    Ann Surg Oncol. 2022;29:5317-5318.
    PubMed    


  85. BITCON C, Whalen S, Coleman J, Rendon R, et al
    Utility of Postoperative Serial Renal Function Monitoring in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma.
    Ann Surg Oncol. 2022;29:5333-5337.
    PubMed    
    Abstract available

  86. MORI K, Schuettfort VM, Katayama S, Laukhtina E, et al
    Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
    Ann Surg Oncol. 2022;29:5307-5316.
    PubMed    
    Abstract available

  87. CHARGARI C, Haie-Meder C, Espenel S, Garcia MA, et al
    Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments.
    Int J Radiat Oncol Biol Phys. 2022;113:602-613.
    PubMed    
    Abstract available

  88. YILDIRIM R, Cansu DU, Korkmaz C
    A Case of Scleromyxedema Development Following Intravesical Bacillus Calmette-Guerin Administration.
    J Rheumatol. 2022;49:858-859.
    PubMed    


  89. MORIZANE S, Honda M, Yumioka T, Iwamoto H, et al
    Technique of en bloc resection of the membranous urethra and bladder during robot-assisted radical cystectomy in patients without simultaneous urethrectomy.
    Asian J Endosc Surg. 2022;15:683-687.
    PubMed    
    Abstract available

  90. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
    PubMed    


  91. TAKADA-OWADA A, Fuchizawa H, Kijima T, Ishikawa M, et al
    Cryptococcal Prostatitis Forming Caseous and Suppurative Granulomas Diagnosed by Needle Biopsy: A Case Report.
    Int J Surg Pathol. 2022;30:586-589.
    PubMed    
    Abstract available

  92. LI Z, Ren D, Chen C, Sun L, et al
    OSU-T315 and doxorubicin synergistically induce apoptosis via mitochondrial pathway in bladder cancer cells.
    Cell Biol Int. 2022 Jul 13. doi: 10.1002/cbin.11855.
    PubMed    
    Abstract available

  93. XIANG Y, Lv D, Song T, Niu C, et al
    Tumor suppressive role of microRNA-139-5p in bone marrow mesenchymal stem cells-derived extracellular vesicles in bladder cancer through regulation of the KIF3A/p21 axis.
    Cell Death Dis. 2022;13:599.
    PubMed    
    Abstract available

  94. AZHATI B, Wu G, Zhan H, Liang W, et al
    Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
    World J Surg Oncol. 2022;20:231.
    PubMed    
    Abstract available

  95. CHEN C, Na X, Wang L, Yu R, et al
    High-throughput screening identifies stevioside as a potent agent to induce apoptosis in bladder cancer cells.
    Biochem Pharmacol. 2022 Jul 9:115166. doi: 10.1016/j.bcp.2022.115166.
    PubMed    
    Abstract available

  96. GUI CP, Li JY, Fu LM, Luo CG, et al
    Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer.
    J Big Data. 2022;9:88.
    PubMed    
    Abstract available

  97. HU SP, Zhang Z, Xiao F, Huang JN, et al
    Paraganglioma of the Urinary Bladder in a Dog.
    J Comp Pathol. 2022;195:1-6.
    PubMed    
    Abstract available

  98. WANG G, Gao Y, Chen Y, Wang K, et al
    Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development.
    Front Oncol. 2022;12:921711.
    PubMed    
    Abstract available

  99. ZHOU Q, Chen S, Lu M, Luo Y, et al
    Erratum: EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/beta-catenin signaling pathway in human bladder cancer: Erratum.
    Int J Biol Sci. 2022;18:3798-3799.
    PubMed    
    Abstract available

  100. WANG L, Wu D, Wu S, Liu Y, et al
    The Effect of Narrative Nursing Intervention on Shame in Elderly Patients with Bladder Cancer after Ileal Bladder Replacement: A Cohort Study.
    Comput Math Methods Med. 2022;2022:4299919.
    PubMed    
    Abstract available

  101. D'ANDREA D, Shariat SF, Soria F, Mari A, et al
    The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy.
    Eur Urol Open Sci. 2022;41:74-80.
    PubMed    
    Abstract available

  102. KULKARNI GS, Lilge L, Nesbitt M, Dumoulin-White RJ, et al
    A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2022;41:105-111.
    PubMed    
    Abstract available

  103. YI X, Zheng X, Xu H, Li J, et al
    IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Front Immunol. 2022;13:898493.
    PubMed    
    Abstract available

  104. BONDARUK J, Jaksik R, Wang Z, Cogdell D, et al
    Erratum: The origin of bladder cancer from mucosal field effects.
    iScience. 2022;25:104715.
    PubMed    
    Abstract available

  105. AYDIN AM, Cheriyan SK, Reich R, Hajiran A, et al
    Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
    Urol Oncol. 2022 Jul 7. pii: S1078-1439(22)00192.
    PubMed    
    Abstract available

  106. CHU C, Pietzak E
    Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue "Seminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma".
    Urol Oncol. 2022 Jul 7. pii: S1078-1439(22)00185.
    PubMed    
    Abstract available

  107. GRUBA N, Musielak M, Rejmak W, Lesner A, et al
    Detection of ADAM15 in urine from patients with bladder cancer.
    Anal Biochem. 2022 Jul 7:114805. doi: 10.1016/j.ab.2022.114805.
    PubMed    
    Abstract available

  108. PAN W, Han J, Wei N, Wu H, et al
    LINC00702-mediated DUSP1 transcription in the prevention of bladder cancer progression: Implications in cancer cell proliferation and tumor inflammatory microenvironment.
    Genomics. 2022 Jul 6:110428. doi: 10.1016/j.ygeno.2022.110428.
    PubMed    
    Abstract available

  109. VADER DT, Parikh RB, Li H, Imai K, et al
    Impact of label restriction on checkpoint-inhibitor use in bladder cancer and changes in mortality.
    JNCI Cancer Spectr. 2022 Jul 9. pii: 6637519. doi: 10.1093.
    PubMed    
    Abstract available

  110. PENA KB, Riu F, Hernandez A, Guilarte C, et al
    Usefulness of the Urine Methylation Test (Bladder EpiCheck((R))) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells-An Institutional Study.
    J Clin Med. 2022;11.
    PubMed    
    Abstract available

  111. WOLLNY T, Wnorowska U, Piktel E, Suprewicz L, et al
    Sphingosine-1-Phosphate-Triggered Expression of Cathelicidin LL-37 Promotes the Growth of Human Bladder Cancer Cells.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  112. PILISZEK R, Brozyna AA, Rudnicki WR
    Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  113. BECKER L, Fischer F, Fleck JL, Harland N, et al
    Data-Driven Identification of Biomarkers for In Situ Monitoring of Drug Treatment in Bladder Cancer Organoids.
    Int J Mol Sci. 2022;23.
    PubMed    
    Abstract available

  114. DE CARLO C, Valeri M, Rudini N, Zucali PA, et al
    Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  115. HU X, Li G, Wu S
    Advances in Diagnosis and Therapy for Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  116. AMANTINI C, Maggi F, Rossi de Vermandois JA, Gubbiotti M, et al
    The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  117. JIANG S, Redelman-Sidi G
    BCG in Bladder Cancer Immunotherapy.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  118. ZHAO X, Zhang L, Bai L, Zhao Y, et al
    Epidemiological analysis of second primary malignant neoplasms in cancer survivors aged 85 years and older: a SEER data analysis (1975-2016).
    Sci Rep. 2022;12:11688.
    PubMed    
    Abstract available

  119. OMORPHOS NP, Ghose A, Hayes JDB, Kandala A, et al
    The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer.
    Urol Oncol. 2022 Jul 5. pii: S1078-1439(22)00187.
    PubMed    
    Abstract available

  120. GRANTZAU T, Toft BG, Melchior LC, Elversang J, et al
    PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study.
    APMIS. 2022;130:498-506.
    PubMed    
    Abstract available

  121. YHIM HY, Jeon SY, Lee CH, Lee NR, et al
    Bilateral pleural effusion associated with atezolizumab in a patient with Lynch syndrome-related urothelial carcinoma: a case report.
    Ann Palliat Med. 2022;11:2162-2169.
    PubMed    
    Abstract available

  122. TAN Z, Jiang Y, Liang L, Wu J, et al
    Dysregulation and prometastatic function of glycosyltransferase C1GALT1 modulated by cHP1BP3/ miR-1-3p axis in bladder cancer.
    J Exp Clin Cancer Res. 2022;41:228.
    PubMed    
    Abstract available


  123. Erratum: Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
    Front Immunol. 2022;13:975797.
    PubMed    
    Abstract available

  124. LIU D, Xu S, Chang T, Ma S, et al
    Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Front Immunol. 2022;13:916800.
    PubMed    
    Abstract available

  125. TENG H, Li Q, Gou M, Liu G, et al
    Lamprey immunity protein enables early detection and recurrence monitoring for bladder cancer through recognizing Neu5Gc-modified uromodulin glycoprotein in urine.
    Biochim Biophys Acta Mol Basis Dis. 2022;1868:166493.
    PubMed    
    Abstract available

  126. OEY O, Viswambaram P, Moe A, Swarbick N, et al
    Anterior pelvic exenteration and synchronous bilateral nephroureterectomy for BK polyoma virus induced urothelial carcinoma of the bladder: A case report.
    Folia Med (Plovdiv). 2022;64:521-526.
    PubMed    
    Abstract available

  127. WU Q, Cai L, Yuan B, Cao Q, et al
    The application value of multi-parameter cystoscope in improving the accuracy of preoperative bladder cancer grading.
    BMC Urol. 2022;22:111.
    PubMed    
    Abstract available

  128. PALACKA P, Janega P, Polakova H, Slopovsky J, et al
    Pericardial malignant infiltration as the cause of sudden death of a patient with metastatic urothelial carcinoma treated with atezolizumab.
    BMC Urol. 2022;22:108.
    PubMed    
    Abstract available

  129. YAMASHITA Y, Miura T, Kawamura S, Sumii K, et al
    [Treatment of Parastomal Hernia Following Robot-Assisted Radical Cystectomy and Cutaneous Ureterostomy : A Case Report].
    Hinyokika Kiyo. 2022;68:197-199.
    PubMed    
    Abstract available

  130. LI Z, Zhou Z, Cui Y, Zhang Y, et al
    Systematic review and meta-analysis of randomized controlled trials of perioperative outcomes and prognosis of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer.
    Int J Surg. 2022;104:106777.
    PubMed    
    Abstract available

  131. LIU S, Shi J, Wang L, Huang Y, et al
    Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling.
    Free Radic Biol Med. 2022;189:42-57.
    PubMed    
    Abstract available

  132. WANG L, Shi J, Liu S, Huang Y, et al
    RAC3 Inhibition Induces Autophagy to Impair Metastasis in Bladder Cancer Cells via the PI3K/AKT/mTOR Pathway.
    Front Oncol. 2022;12:915240.
    PubMed    
    Abstract available

  133. MOKKAPATI S, Narayan VM, Manyam GC, Lim AH, et al
    Lentiviral interferon: A novel method for gene therapy in bladder cancer.
    Mol Ther Oncolytics. 2022;26:141-157.
    PubMed    
    Abstract available

  134. SUN X, Xin S, Li W, Zhang Y, et al
    Discovery of Notch Pathway-Related Genes for Predicting Prognosis and Tumor Microenvironment Status in Bladder Cancer.
    Front Genet. 2022;13:928778.
    PubMed    
    Abstract available

  135. ZHANG X, Liang H, Tang Q, Chen H, et al
    Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer.
    Front Genet. 2022;13:801665.
    PubMed    
    Abstract available

  136. WARE AP, Kabekkodu SP, Chawla A, Paul B, et al
    Diagnostic and prognostic potential clustered miRNAs in bladder cancer.
    3 Biotech. 2022;12:173.
    PubMed    
    Abstract available

  137. CABALLERO JM, Perez-Marquez M, Gili JM, Pereira JC, et al
    Environmental Factors Involved in the High Incidence of Bladder Cancer in an Industrialized Area in North-Eastern Spain.
    J Environ Public Health. 2022;2022:1051046.
    PubMed    
    Abstract available

  138. LI J, Liang Y, Fan J, Xu C, et al
    DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma.
    BMC Med. 2022;20:222.
    PubMed    
    Abstract available

  139. AHMED ME, Todenhofer T, Karnes RJ, Seiler R, et al
    Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers.
    Eur Urol Focus. 2022 Jul 14. pii: S2405-4569(22)00138.
    PubMed    
    Abstract available

  140. TANG F, Yu H, Wang X, Shi J, et al
    NCAPG promotes tumorigenesis of bladder cancer through NF-kappaB signaling pathway.
    Biochem Biophys Res Commun. 2022;622:101-107.
    PubMed    
    Abstract available

  141. SINHA A, Patterson B
    Persistently elevated beta-human chorionic gonadotropin level after vacuum-assisted uterine aspiration: a case report.
    J Med Case Rep. 2022;16:279.
    PubMed    
    Abstract available

  142. FURUYA H, Sasaki Y, Chen R, Peres R, et al
    PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity.
    Sci Rep. 2022;12:12186.
    PubMed    
    Abstract available

  143. XU H, Cao X, Zhang W, Li Q, et al
    Co-existence of two ciprofloxacin-resistant Salmonella enterica serovar Kentucky strains in the urine of a bladder cancer patient.
    J Glob Antimicrob Resist. 2022 Jul 13. pii: S2213-7165(22)00177.
    PubMed    


  144. CONCONI D, Jemma A, Giambra M, Redaelli S, et al
    Analysis of copy number alterations in bladder cancer stem cells revealed a prognostic role of LRP1B.
    World J Urol. 2022 Jul 16. pii: 10.1007/s00345-022-04093.
    PubMed    
    Abstract available

  145. BARAU C, Maille P, Sirab N, Ghaleh B, et al
    Automated DNA, RNA, and Protein Extraction from Urine for Biobanking.
    J Biomol Tech. 2022;33.
    PubMed    
    Abstract available

  146. LUO H, Xu C, Ge B, Wang T, et al
    CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150: A Comprehensive Pan-Cancer and Bioinformatics Study.
    Comput Math Methods Med. 2022;2022:8100325.
    PubMed    
    Abstract available

  147. ZHANG W, He X, Yin H, Cao W, et al
    Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis.
    J Hematol Oncol. 2022;15:93.
    PubMed    
    Abstract available

  148. HUANG Z, Yan Y, Wang T, Wang Z, et al
    Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.
    J Transl Med. 2022;20:315.
    PubMed    
    Abstract available

  149. CHEN J, Gu Z, Pan Y, Zhang Y, et al
    Effect of Radical Laparoscopic Surgery and Conventional Open Surgery on Surgical Outcomes, Complications, and Prognosis in Elderly Patients with Bladder Cancer.
    Evid Based Complement Alternat Med. 2022;2022:1681038.
    PubMed    
    Abstract available

  150. YONG C, Mott SL, Steinberg RL, Packiam VT, et al
    A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience.
    Urol Oncol. 2022 Jul 10. pii: S1078-1439(22)00226.
    PubMed    
    Abstract available

  151. WISHAHI M, Otto T, Golka K
    Re: bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis-are they the same tumors?
    World J Urol. 2022;40:2139-2140.
    PubMed    


  152. BALASUBRAMANYA R, Shanbhogue AK, Ramani NS, Morani AC, et al
    Mesenchymal neoplasms of the urinary bladder: a comprehensive review with focus on cross-sectional imaging findings.
    Abdom Radiol (NY). 2022;47:2881-2895.
    PubMed    
    Abstract available

  153. CARVALHO FLF, Wang Y, Dall CP, Nayan M, et al
    Preoperative anemia is associated with increased radical cystectomy complications.
    Urol Oncol. 2022;40:382.
    PubMed    
    Abstract available

  154. BURGESS EF, Sanders JA, Livasy C, Symanowski J, et al
    Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes.
    Urol Oncol. 2022;40:383.
    PubMed    
    Abstract available

  155. FU T, Lin Y, Lin L, Yang Y, et al
    Network architecture of non-coding RNAs provides insights into the pathogenesis of upper tract urothelial carcinoma.
    Urol Oncol. 2022;40:383.
    PubMed    
    Abstract available

  156. SONG Y, Han J, Qin C, Du Y, et al
    Whether diagnostic ureteroscopic biopsy and ureteroscopy without biopsy have different impacts on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy?
    World J Urol. 2022;40:2135-2137.
    PubMed    


  157. MATTE P, Campedel L
    [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
    Bull Cancer. 2022;109.
    PubMed    


  158. IWAMURA H, Mizuno K, Akamatsu S, Hatakeyama S, et al
    Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.
    Cancer Sci. 2022;113:2434-2445.
    PubMed    
    Abstract available

  159. DUM D, Taherpour N, Menz A, Hoflmayer D, et al
    Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
    Pathobiology. 2022;89:245-258.
    PubMed    
    Abstract available

  160. MEDINA LG, Alsyouf M, Ghoreifi A, Sayegh AS, et al
    Distal ureter and bladder cuff excision using the "Keyhole Technique" during Robotic Radical Nephroureterectomy.
    Int Braz J Urol. 2022;48:876-877.
    PubMed    
    Abstract available

  161. HOANG TT, Mandleywala K, Viray T, Tan KV, et al
    EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.
    Mol Imaging Biol. 2022;24:511-518.
    PubMed    
    Abstract available

  162. CANCRINI F, Michel F, Cussenot O, Alshehhi H, et al
    Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?
    World J Urol. 2022;40:1949-1959.
    PubMed    
    Abstract available

  163. KIM R, Hong JY, Lee J, Kwon GY, et al
    Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.
    Cancer Res Treat. 2022;54:894-906.
    PubMed    
    Abstract available

  164. LI Y, Xiao M, Xiao L
    Report of a case of paraganglioma of the urinary bladder: a discussion of the surgical approach.
    Minerva Surg. 2022;77:416-418.
    PubMed    


  165. HWANG I, Park I, Yoon SK, Lee JL, et al
    Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor.
    Asia Pac J Clin Oncol. 2022;18:371-377.
    PubMed    
    Abstract available

  166. LAYMON M, Mosbah A, Hashem A, Elsawy AA, et al
    Predictors and survival benefit of achieving pentafecta in a contemporary series of open radical cystectomy.
    Minerva Urol Nephrol. 2022;74:428-436.
    PubMed    
    Abstract available

  167. ANDERSON JA, Matoso A, Murati Amador BI, Cheng L, et al
    Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study.
    Pathology. 2021;53:214-219.
    PubMed    
    Abstract available

  168. INOUE S, Sassa N, Kawanishi H, Yuguchi Y, et al
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
    Anticancer Res. 2022;42:3627-3636.
    PubMed    
    Abstract available

  169. DENG F, Kong MX, Lai J
    Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
    Anticancer Res. 2022;42:3601-3605.
    PubMed    
    Abstract available

  170. WALLACE B, Dekalo S, Kabha M, Mintz I, et al
    Can We Predict a Higher Risk of Urothelial Bladder Cancer With a Simple Blood Test?
    Anticancer Res. 2022;42:3569-3573.
    PubMed    
    Abstract available

  171. DADIKHI K, Mueller F, Montani M, Thalmann GN, et al
    Case of the Month from the University Hospital of Bern, Switzerland: Urothelial carcinoma in an orthotopic neobladder: reported cases and pathophysiological hypotheses.
    BJU Int. 2022;130:38-42.
    PubMed    


  172. LOIZZO D, Pandolfo SD, Del Giudice F, Cerrato C, et al
    Ureteroscopy and tailored treatment of upper tract urothelial cancer: recent advances and unmet needs.
    BJU Int. 2022;130:35-37.
    PubMed    


  173. MAIBOM SL, Roder MA, Aasvang EK, Rohrsted M, et al
    Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study.
    BJU Int. 2022;130:102-113.
    PubMed    
    Abstract available

  174. AHMADI H, Ladi-Seyedian SS, Konety B, Pohar K, et al
    Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry.
    BJU Int. 2022;130:62-67.
    PubMed    
    Abstract available

  175. GRAHN A, Eisfeldt J, Malm C, Foroughi Asl H, et al
    Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
    BJU Int. 2022;130:92-101.
    PubMed    
    Abstract available

  176. WALRAVEN JEW, Ripping TM, Oddens JR, van Rhijn BWG, et al
    The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer.
    BJU Int. 2022 Jul 21. doi: 10.1111/bju.15856.
    PubMed    
    Abstract available

  177. AHMADI H, Reddy S, Nguyen C, Douglawi A, et al
    Long-term renal function in patients with chronic kidney disease following radical cystectomy and orthotopic neobladder.
    BJU Int. 2022;130:200-207.
    PubMed    
    Abstract available

  178. KOBAYASHI M, Narita S, Matsui Y, Kanda S, et al
    Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
    BJU Int. 2022;130:226-234.
    PubMed    
    Abstract available

  179. TOMIYAMA E, Fujita K, Matsuzaki K, Narumi R, et al
    EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer.
    Br J Cancer. 2022 Jul 6. pii: 10.1038/s41416-022-01860.
    PubMed    
    Abstract available

  180. MARTINI A, Yu M, Raggi D, Joshi H, et al
    Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring.
    Cancer. 2022;128:2892-2897.
    PubMed    
    Abstract available

  181. PIETZAK EJ, Whiting K, Srinivasan P, Bandlamudi C, et al
    Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2022 Jul 14. pii: 707011. doi: 10.1158/1078-0432.CCR-22-1006.
    PubMed    
    Abstract available

  182. HEESAKKERS JPFA, Witjes F
    Editorial: Medical, technical and functional aspect of various types of urinary diversion.
    Curr Opin Urol. 2021;31:542-543.
    PubMed    


  183. GRAUER R, Wiklund NP
    Update on robotic cystectomy.
    Curr Opin Urol. 2021;31:537-541.
    PubMed    
    Abstract available

  184. LIEDBERG F, Bobjer J
    Urinary diversions for benign and oncologic indications: what did we learn about short term complications in the last 24 months?
    Curr Opin Urol. 2021;31:556-561.
    PubMed    
    Abstract available

  185. NUIJENS ST, Cobussen-Boekhorst H, Heesakkers JPFA, Witjes JA, et al
    Patient-reported outcomes and health-related quality of life after urinary diversions.
    Curr Opin Urol. 2021;31:574-579.
    PubMed    
    Abstract available

  186. VAN 'T HOF MEM, Bruins HM, van Roermund JGH
    Management of upper urinary tract problems after radical cystectomy for urothelial carcinoma: tips and tricks.
    Curr Opin Urol. 2021;31:570-573.
    PubMed    
    Abstract available

  187. LONATI C, Simeone C, Suardi N, Briganti A, et al
    Micropapillary bladder cancer: an evolving biology.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00030.
    PubMed    
    Abstract available

  188. SCHOBER JP, Plimack E, Geynisman D, Zibelman M, et al
    The past, present, and future of pT0 in bladder cancer clinical trials.
    Curr Opin Urol. 2022 Jul 19. pii: 00042307-990000000-00026.
    PubMed    
    Abstract available

  189. SORIA F, Dutto D, Gontero P
    Clinical and biological markers for risk-stratification of T1 high-grade non-muscle invasive bladder cancer.
    Curr Opin Urol. 2022 Jul 15. pii: 00042307-990000000-00019.
    PubMed    
    Abstract available

  190. TAKAHASHI T
    Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.o
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02466.
    PubMed    


  191. ADELEKE S, Tocco B, Kasivisvanathan V
    Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02470.
    PubMed    


  192. SZABADOS B, Kockx M, Assaf ZJ, van Dam PJ, et al
    Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Eur Urol. 2022;82:212-222.
    PubMed    
    Abstract available

  193. RAI BP, Luis Dominguez Escrig J, Vale L, Kuusk T, et al
    Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.
    Eur Urol. 2022;82:182-192.
    PubMed    
    Abstract available

  194. TANAKA T, Shindo T, Hashimoto K, Kobayashi K, et al
    Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: A single tertiary center experience.
    Int J Urol. 2022 Jun 30. doi: 10.1111/iju.14970.
    PubMed    
    Abstract available

  195. ISHIYAMA Y
    Editorial Comment to Impact of early postoperative creatinine increase on mid-term renal function after cystectomy.
    Int J Urol. 2022;29:724.
    PubMed    


  196. MASTROIANNI R, Simone G
    Editorial Comment to Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:684.
    PubMed    


  197. SARI MOTLAGH R, Schuettfort VM, Mori K, Katayama S, et al
    Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:676-683.
    PubMed    
    Abstract available

  198. TOGASHI K, Hatakeyama S, Yoneyama T, Hamaya T, et al
    Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Int J Urol. 2022;29:733-739.
    PubMed    
    Abstract available

  199. KITA Y, Ito K, Sano T, Hashimoto K, et al
    Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Int J Urol. 2022;29:647-655.
    PubMed    
    Abstract available

  200. IDE H
    Editorial Comment from Dr Ide to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14988.
    PubMed    


  201. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.15000.
    PubMed    


  202. TOCHIGI K, Nagayama J, Bando S, Ishiyama A, et al
    Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14974.
    PubMed    
    Abstract available

  203. MURAKAMI Y, Matsumoto K, Miyake M, Amano N, et al
    Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14976.
    PubMed    
    Abstract available

  204. JAFFER A, Lee M, Khalil O, Raslan M, et al
    The natural history of low-risk non-muscle-invasive bladder cancer: a collaborative multi-centre study.
    Int Urol Nephrol. 2022 Jun 27. pii: 10.1007/s11255-022-03264.
    PubMed    
    Abstract available

  205. SAINI S, Pathak RA, Hemal AK
    Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care?
    Int Urol Nephrol. 2022;54:1777-1785.
    PubMed    
    Abstract available

  206. GRIMM MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, et al
    Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
    J Clin Oncol. 2022;40:2128-2137.
    PubMed    
    Abstract available

  207. MCELREE IM, Packiam VT, Steinberg RL, Mott SL, et al
    Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment OF NON-MUSCLE Invasive Bladder Cancer.
    J Urol. 2022 Jul 5:101097JU0000000000002848. doi: 10.1097/JU.0000000000002848.
    PubMed    
    Abstract available

  208. BREE KK, Hensley PJ, Lobo N, Brooks NA, et al
    All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guerin Response in High-Grade Ta Tumors.
    J Urol. 2022;208:284-291.
    PubMed    
    Abstract available

  209. HAKIMI K, Carbonara U, Djaladat H, Mehrazin R, et al
    Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry.
    J Urol. 2022;208:268-276.
    PubMed    
    Abstract available

  210. LIU F, Zhang H, Xie F, Tao D, et al
    Correction: Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis.
    Oncogene. 2022 Jul 7. pii: 10.1038/s41388-022-02358.
    PubMed    


  211. BENIDIR T, Lone Z, Zhang A, Nowacki AS, et al
    Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer when treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy.
    Urology. 2022 Jun 27. pii: S0090-4295(22)00514.
    PubMed    
    Abstract available

  212. ISCAIFE A, Ribeiro Filho LA, Aparecido Pereira MW, Gallucci FP, et al
    Holmium Laser Resection of Large Bladder Tumors: Technique Description, Feasibility, and Histopathological Quality Analysis.
    Urology. 2022;165:373.
    PubMed    
    Abstract available

  213. ALSYOUF M, Daneshmand S
    Re: Detection Rate of CIS During TURBT Following Shift From PDD to NBI in a Single University Hospital.
    Urology. 2022;165:e47.
    PubMed    


  214. RASMUSSEN M, Madsen MG, Therkildsen C
    Immunohistochemical Screening of Upper Tract Urothelial Carcinomas for Lynch Syndrome Diagnostics: A Systematic Review.
    Urology. 2022;165:44-53.
    PubMed    
    Abstract available

  215. KHONDAKAR NR, Lee P, McNeil BK
    Gross Hematuria in an Adolescent Secondary to a Rare Bladder Tumor: A Case Report and Review of Inflammatory Myofibroblastic Tumors of the Urinary Bladder.
    Urology. 2022;165:e39-e45.
    PubMed    
    Abstract available

  216. TSIVIAN M, Bole R, Packiam VT, Boorjian SA, et al
    The Association of Trainee Involvement in Radical Cystectomy With Perioperative and Oncologic Outcomes.
    Urology. 2022;165:128-133.
    PubMed    
    Abstract available

  217. HOU J, Lu Z, Cheng X, Dong R, et al
    Ferroptosis-related long non-coding RNA signature predicts the prognosis of bladder cancer.
    BMC Cancer. 2022;22:719.
    PubMed    
    Abstract available

  218. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
    Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    BMC Cancer. 2022;22:713.
    PubMed    
    Abstract available

  219. KIM GT, Kim EY, Shin SH, Lee H, et al
    Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma.
    BMC Cancer. 2022;22:727.
    PubMed    
    Abstract available

  220. MIYAI K, Kawamura K, Ito K, Matsukuma S, et al
    Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.
    BMC Cancer. 2022;22:787.
    PubMed    
    Abstract available

  221. CHEN M, Chan RWY, Cheung PPH, Ni M, et al
    Fragmentomics of urinary cell-free DNA in nuclease knockout mouse models.
    PLoS Genet. 2022;18:e1010262.
    PubMed    
    Abstract available

  222. GULYAS D, Kovacs G, Jankovics I, Meszaros L, et al
    Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model.
    PLoS One. 2022;17:e0270802.
    PubMed    
    Abstract available

  223. GLEICHENHAGEN J, Arndt C, Casjens S, Topfer C, et al
    Exploring solid-phase proximity ligation assay for survivin detection in urine.
    PLoS One. 2022;17:e0270535.
    PubMed    
    Abstract available

  224. JURI H, Higashiyama A, Yamamoto K, Narumi Y, et al
    Comparison of reduced field-of-view DWI and full field-of view DWI for the differentiation between non-muscle invasive bladder cancer and muscle invasive bladder cancer using VI-RADS.
    PLoS One. 2022;17:e0271470.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;